Belgium· BE-AMP-SAM509466-00
Zinplava 25 mg/ml
A bezlotoxumab product containing bezlotoxumab, registered in Belgium by Merck Sharp & Dohme. The same ATC class is registered in 9 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Bezlotoxumab is registered in 9 of 19 countries.
Countries holding a registration under ATC J06BC03 (bezlotoxumab), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 6 of them publish a price we can compare per daily dose
Bezlotoxumab · ATC J06BC03
9 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Bezlotoxumab
- Manufacturer
- Merck Sharp & Dohme
- Country
- Belgium (BE)
- ATC code
- J06BC03
- ATC class
- Bezlotoxumab
- Defined daily dose
- 0.7 g, P
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Bezlotoxumab in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaZINPLAVAMerck Sharp & Dohme B.V., Haarlem
- FinlandZINPLAVAMerck Sharp & Dohme B.V.
- IcelandZinplavaMerck Sharp & Dohme B.V.*
- PolandZinplavaMerck Sharp & Dohme B.V.
- SwedenZINPLAVA 25 mg/ml Koncentrat till infusionsvätska, lösningMerck Sharp & Dohme BV
- IrelandZINPLAVA 25 mg/mL concentrate for solution for infusionMerck Sharp & Dohme BV
- SpainZINPLAVA 25 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSIONMerck Sharp & Dohme B.V.
- FranceZINPLAVA 25 mg/mL, solution à diluer pour perfusionMERCK SHARP & DOHME (PAYS-BAS)
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Zinplava
- Liechtenstein · Zinplava
- Norway · Zinplava
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/58a71abf-d77b-4a21-81e0-81692a0c3bc0 GET /v1/drugs/58a71abf-d77b-4a21-81e0-81692a0c3bc0?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Concentrate for solution for infusion",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Zinplava 25 mg/ml",
"name_fr": "Zinplava 25 mg/ml",
"name_nl": "Zinplava 25 mg/ml",
"amp_code": "SAM509466-00",
"strengths": [
"25.0000",
"4.5700"
],
"pack_count": 1,
"substances": [
"Bezlotoxumab",
"Polysorbate 80",
"Sodium"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Bezlotoxumab",
"authorisation_numbers": [
"EU/1/16/1156/001"
]
}See everything about bezlotoxumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.